As of Jan 29, 2025, Insmed Incorporated Intrinsic Value is $27.1. This suggests it may be overvalued by 65.2% compared to its current price of around $78.0.
As of Jan 29, 2025, Insmed Incorporated's Discounted Cash Flow (DCF) valuation estimates its share price at N/A. This suggests it may be overvalued by N/A to its current price of around $78.0, using a discount rate of 9.2% and terminal growth rate of 3.0%.
Insmed Incorporated is currently considered overvalued based on its Discounted Cash Flow (DCF) valuation and Relative Valuation, which estimates its share price to be $27.1, compared to a market price of around $78.0. This suggests a potential overvaluation of 65.2%.